| Goodwill |
The changes in the carrying value of goodwill for the period presented are as follows (in thousands):
| | | | | | | | | | | | | | | | | | | Carrying
Value | | Balance as of December 31, 2025 | | | | | | $ | 278,325 | | Addition from acquisitions and related adjustments(1) | | | | | | 858,813 | | | Foreign currency translation adjustments | | | | | | (35,418) | | | Balance as of June 30, 2026 | | | | | | $ | 1,101,720 | |
______________ (1)Includes the goodwill acquired in connection with the YourBio merger and Eucalyptus acquisition, as well as measurement period adjustments related to the fair values of the assets acquired and liabilities assumed in the Zava business combination. These adjustments did not have a material impact on goodwill. See Note 3 – Acquisitions for further details.
|
| Intangible Asset, Finite-Lived |
Intangible assets, net as of June 30, 2026 consist of the following (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Gross
Amount | | Accumulated
Amortization
and Impairment | | Net
Carrying
Value | | Weighted
Average
Remaining
Useful Life
(Years) | | Trade names | | $ | 122,930 | | | $ | (21,316) | | | $ | 101,614 | | | 2.8 | | Platform partnerships | | 97,181 | | | (8,098) | | | 89,083 | | | 11.0 | | Developed intellectual property | | 89,300 | | | (2,960) | | | 86,340 | | | 14.6 | | Developed technology | | 81,376 | | | (6,907) | | | 74,469 | | | 3.9 | | Customer relationships | | 51,256 | | | (9,097) | | | 42,159 | | | 1.7 | | 503B pharmacy license | | 28,596 | | | (5,243) | | | 23,353 | | | 8.2 | | Other | | 17,313 | | | (11,522) | | | 5,791 | | | 5.0 | | Intangible assets, net | | $ | 487,952 | | | $ | (65,143) | | | $ | 422,809 | | | 7.3 |
Intangible assets, net as of December 31, 2025 consist of the following (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Gross
Amount | | Accumulated
Amortization
and Impairment | | Net
Carrying
Value | | Weighted
Average
Remaining
Useful Life
(Years) | | Platform partnerships | | $ | 99,964 | | | $ | (4,165) | | | $ | 95,799 | | | 11.5 | | Trade names | | 33,031 | | | (14,951) | | | 18,080 | | | 2.3 | | 503B pharmacy license | | 28,596 | | | (3,813) | | | 24,783 | | | 8.7 | | Developed technology | | 27,796 | | | (2,921) | | | 24,875 | | | 4.3 | | Customer relationships | | 18,081 | | | (3,424) | | | 14,657 | | | 1.7 | | Other | | 23,331 | | | (5,409) | | | 17,922 | | | 2.7 | | Intangible assets, net | | $ | 230,799 | | | $ | (34,683) | | | $ | 196,116 | | | 7.8 |
|
| Finite-lived Intangible Assets Amortization Expense |
Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to June 30, 2026 is as follows (in thousands):
| | | | | | | | | | The remainder of 2026 | | $ | 52,233 | | 2027 | | 97,025 | | 2028 | | 76,113 | | 2029 | | 48,065 | | 2030 | | 25,283 | | 2031 and thereafter | | 124,090 | | | $ | 422,809 |
|